Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, China.
Int J Nanomedicine. 2011;6:1167-84. doi: 10.2147/IJN.S21445. Epub 2011 Jun 9.
The purpose of this study was to develop folate-poly (PEG-cyanoacrylate-co-cholesteryl cyanoacrylate) (FA-PEG-PCHL)-modified freeze-dried liposomes for targeted chemotherapy using docetaxel as a model drug.
FA-PEG-PCHL was synthesized and its cytotoxicity was evaluated by CCK-8 assay in L929. Docetaxel-loaded liposomes modified by FA-PEG-PCHL were prepared by an organic solvent injection method and lyophilized to obtain freeze-dried FA-PEG-PCHL-docetaxel liposomes (FA-PDCT-L). Two carcinoma cell lines (MCF-7 and A-549 cells) were cultured with docetaxel solution, conventional docetaxel-loaded liposomes, or FA-PDCT-L, and the cytotoxicity and apoptosis was evaluated for each preparation. The uptake of the docetaxel preparations into MCF-7 cells was studied by confocal laser scanning microscopy. Liquid chromatography-mass spectrometry was used to study the pharmacokinetics and tissue distribution characteristics of the preparations.
The existence of an enlarged fixed aqueous layer on the surface of the liposomes was affirmed by zeta potential analysis. The entrapment efficiency and particle size distribution were almost the same as those of docetaxel-loaded liposomes. The drug release profile showed that the release rate was faster at higher molecular weight of the polymer. Compared with docetaxel solution and docetaxel-loaded liposomes, FA-PDCT-L demonstrated the strongest cytotoxicity against two carcinoma cell lines, the greatest intracellular uptake especially in the nucleus, as well as the most powerful apoptotic efficacy. In pharmacokinetic studies, the area under the plasma concentration-time curve of FA-PDCT-L was increased 3.82 and 6.23 times in comparison with the values for the docetaxel-loaded liposomes and docetaxel solution, respectively. Meanwhile, a lower concentration of docetaxel was observed for FA-PDCT-L in the liver and spleen, and a significantly higher concentration of FA-PDCT-L in tumors suggested that the presence of FA-PEG-PCHL on the liposomes resulted in greater accumulation of the drug in tumor tissue.
Liposomes modified by FA-PEG-PCHL could be one of the promising suspensions for the delivery of antitumor drugs in cancer.
本研究旨在开发叶酸-聚(PEG-氰基丙烯酸酯-co-胆甾醇氰基丙烯酸酯)(FA-PEG-PCHL)修饰的冻干脂质体,以多西他赛为模型药物进行靶向化疗。
合成 FA-PEG-PCHL,并通过 CCK-8 法在 L929 中评估其细胞毒性。采用有机溶剂注入法制备 FA-PEG-PCHL 修饰的多西他赛载药脂质体,冻干得到冻干 FA-PEG-PCHL-多西他赛脂质体(FA-PDCT-L)。将两种癌细胞系(MCF-7 和 A-549 细胞)分别用多西他赛溶液、常规多西他赛载药脂质体或 FA-PDCT-L 培养,评价各制剂的细胞毒性和细胞凋亡。通过共聚焦激光扫描显微镜研究多西他赛制剂在 MCF-7 细胞中的摄取情况。采用液相色谱-质谱法研究制剂的药代动力学和组织分布特征。
通过表面等电点分析证实了脂质体表面存在扩大的固定水层。包封效率和粒径分布几乎与多西他赛载药脂质体相同。药物释放曲线表明,聚合物分子量越高,释放速度越快。与多西他赛溶液和多西他赛载药脂质体相比,FA-PDCT-L 对两种癌细胞系的细胞毒性最强,细胞内摄取量最大,特别是在细胞核内,且凋亡效果最强。在药代动力学研究中,FA-PDCT-L 的血浆浓度-时间曲线下面积分别比多西他赛载药脂质体和多西他赛溶液增加了 3.82 倍和 6.23 倍。同时,FA-PDCT-L 在肝脏和脾脏中的药物浓度较低,在肿瘤中的药物浓度明显较高,提示脂质体上存在 FA-PEG-PCHL 导致药物在肿瘤组织中的积累增加。
FA-PEG-PCHL 修饰的脂质体可能是抗肿瘤药物输送的有前途的制剂之一。